Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no b
 

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

More...